US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales.
The bispecific B-cell maturation antigen-directed CD3 T-cell engager will be given to those who have had at least three treatments for the disease.
These three treatments must have included an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody. The patients’ cancer also must have progressed since their last treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze